Brookline upgraded Verrica Pharmaceuticals (VRCA) to Buy from Hold with a $17 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
- Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns
- Verrica Pharmaceuticals Secures $50M Financing Deal
- Verrica Pharmaceuticals announces private placement financing of $50M
- Verrica Pharmaceuticals Reports Strong Growth Amid Challenges